Chris Chen, WuXi Biologics CEO (Anthony Kwan/Bloomberg via Getty Images)

WuXi Bi­o­log­ics seeks spin­out, HK list­ing of bio­con­ju­gates-fo­cused joint ven­ture

An­oth­er mem­ber of the WuXi AppTec fam­i­ly is set to be spun off and sep­a­rate­ly list­ed on the Hong Kong Stock Ex­change, al­low­ing the con­tract re­search, de­vel­op­ment and man­u­fac­tur­ing con­glom­er­ate to branch out even fur­ther.

The pro­posed list­ing would look to raise $500 mil­lion, the In­ter­na­tion­al Fi­nanc­ing Re­view re­ports.

WuXi XDC, the sub­sidiary in ques­tion, is a joint ven­ture be­tween WuXi Bi­o­log­ics — the Hong Kong-list­ed bi­o­log­ics-fo­cused arm — and WuXi STA, which spe­cial­izes in small mol­e­cules and pep­tides. Formed in June 2021, it of­fers con­tract ser­vices re­lat­ing to bio­con­ju­gates, in­clud­ing an­ti­body-drug con­ju­gates, pep­tide con­ju­gates, oli­go con­ju­gates and more.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.